Double-masked, randomized, dose-response study of AR-13324 versus latanoprost in patients with elevated intraocular pressure

Ophthalmology

Volumn 122, Issue 2, 2015, Pages 302-307

  Bacharach, Jason ^a   Dubiner, Harvey B ^b   Levy, Brian ^c   Kopczynski, Casey C ^c   Novack, Gary D ^d  

^a North Bay Eye Associates   (United States)

^b Clayton Eye Clinical Research   (United States)

^c and Durham   (United States)

^d PHARMALOGIC DEVELOPMENT INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AR 13324; EYE DROPS; LATANOPROST; RHO KINASE INHIBITOR; UNCLASSIFIED DRUG; ANTIHYPERTENSIVE AGENT; NORADRENALIN TRANSPORTER; PROSTAGLANDIN F; RHO KINASE;

ABNORMAL SENSATION; ADULT; AGED; ARTICLE; BIOMICROSCOPY; CLINICAL ARTICLE; CONJUNCTIVAL HEMORRHAGE; CONJUNCTIVAL HYPEREMIA; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOREIGN BODY SENSATION; HUMAN; INCIDENCE; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; LACRIMATION DISORDER; MALE; OPEN ANGLE GLAUCOMA; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG EFFECTS; GLAUCOMA, OPEN-ANGLE; MIDDLE AGED; MULTICENTER STUDY; OCULAR HYPERTENSION; OCULOPLETHYSMOGRAPHY; TOPICAL DRUG ADMINISTRATION; VERY ELDERLY; YOUNG ADULT;

ADMINISTRATION, TOPICAL; ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; DOUBLE-BLIND METHOD; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; PROSTAGLANDINS F, SYNTHETIC; RHO-ASSOCIATED KINASES; TONOMETRY, OCULAR; YOUNG ADULT;

EID: 84921539331     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2014.08.022     Document Type: Article

References (16)

1. AGIS Investigators The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration Am J Ophthalmol 130 2000 429 440
2. A. Heijl, M.C. Leske, and B. Bengtsson Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial Arch Ophthalmol 120 2002 1268 1279
3. M.A. Kass, D.K. Heuer, and E.J. Higginbotham Ocular Hypertension Treatment Study Group. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma Arch Ophthalmol 120 2002 701 713
4. P.R. Lichter, D.C. Musch, B.W. Gillespie CIGTS Study Group Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery Ophthalmology 108 2001 1943 1953
5. C.B. Toris, M.L. Gleason, C.B. Camras, and M.E. Yablonski Effects of brimonidine on aqueous humor dynamics in human eyes Arch Ophthalmol 113 1995 1514 1517
6. M.A. Kass, M.O. Gordon, and F. Gao Ocular Hypertension Treatment Study Group. Delaying treatment of ocular hypertension: the Ocular Hypertension Treatment Study Arch Ophthalmol 128 2010 276 287
7. N.K. Janz, P.A. Wren, P.R. Lichter CIGTS Study Group The Collaborative Initial Glaucoma Treatment Study: interim quality of life findings after initial medical or surgical treatment of glaucoma Ophthalmology 108 2001 1954 1965
8. R.F. Brubaker Targeting outflow facility in glaucoma management Survey Ophthalmol 48 suppl 2003 S17 20
9. G.D. Novack Rho kinase inhibitors for the treatment of glaucoma Drugs Future 38 2013 107 113
10. R.D. Williams, G.D. Novack, T. van Haarlem, and C. Kopczynski AR-12286 Phase 2A Study Group. Ocular hypotensive effect of the Rho kinase inhibitor AR-12286 in patients with glaucoma and ocular hypertension Am J Ophthalmol 152 2011 834 841
11. Wang RF, Williamson JE, Kopczynski C, Serle JB. Effect of 0.04% AR-13324, a ROCK and norepinephrine transporter inhibitor, on aqueous humor dynamics in normotensive monkey eyes [report online]. J Glaucoma. Available at: www.journals.lww.com/glaucomajournal/Abstract/publishahead/Effect-of-0-04-AR-13324-a-ROCK,-and.99367.aspx. Accessed August 17, 2014.
12. J.L. Stone, A.L. Robin, and G.D. Novack An objective evaluation of eye-drop instillation in glaucoma patients Arch Ophthalmol 127 2009 732 736
13. M.B. Sherwood, E.R. Craven, and C. Chou Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial Arch Ophthalmol 124 2006 1230 1238
14. B.A. Hughes, J. Bacharach, and E.R. Craven A three-month, multicenter, double-masked study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to travoprost 0.004% ophthalmic solution and timolol 0.5% dosed concomitantly in subjects with open angle glaucoma or ocular hypertension J Glaucoma 14 2005 392 399
15. K. Hedman, and A. Alm A pooled-data analysis of three randomized, double-masked, six-month clinical studies comparing the intraocular pressure reducing effect of latanoprost and timolol Eur J Ophthalmol 10 2000 95 104
16. H. Watabe, S. Abe, and T. Yoshitomi Effects of Rho-associated protein kinase inhibitors Y-27632 and Y-39983 on isolated rabbit ciliary arteries Jpn J Ophthalmol 55 2011 411 417